Evercore ISI Group Maintains Outperform on Halozyme Therapeutics, Raises Price Target to $125

Benzinga · 1d ago
Evercore ISI Group analyst Michael DiFiore maintains Halozyme Therapeutics (NASDAQ:HALO) with a Outperform and raises the price target from $123 to $125.